La vendita allo scoperto per Chemed dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Chemed. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Chemed (NYSE:CHE) Azioni, Report sulle vendite allo scoperto

Chemed

Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.

Chemed Corp

CHENGHE ACQUISITION CO L A

CHINA EASTN AIRL LTD H by China Eastern Airlines Corp. Ltd.

China Eastern Airlines Corp Ltd

CHENGHE ACQUISITION CO UNIT 1 CL A & 1/2 WT EXP

Chenghe Acquisition II Co. Class A Ordinary Shares

Chenghe Acquisition II Co

Chenghe Acquisition II Co. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant

Chenghe Acquisition II Co. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50

The Chefs' Warehouse, Inc. - Common Stock

The Chefs' Warehouse Inc

Check-Cap Ltd

CHAMPION ELEC METALS INC by CHAMPION ELEC METALS INC.

Champion Electric Metals Inc

Cochlear Ltd

Tranchess

CHARGING ROBOTICS INC by Charging Robotics Inc.

Charging Robotics Inc

CHEX - United States Dollar

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and lowers the price target from $697 to $633.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $633

WIIM

Chemed shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 EPS guidance below estimates.

Guidance

Chemed Sees FY24 EPS $23.00-$23.15 Vs $23.58 Est.

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) reported quarterly earnings of $5.64 per share which missed the analyst consensus estimate of $5.76 by 2.08 percent. The company reported quarterly sales of $606.181 million which missed the analyst consensus estimate of $612.215 million by 0.99 percent. This is a 7.38 percent increase over sales of $564.532 million the same period last year.

Earnings

Earnings Misses

Chemed Q3 2024 Adj. EPS $5.64 Misses $5.76 Estimate, Sales $606.181M Miss $612.215M Estimate

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has risen 3.3% since its last report. The company recently reported that it has 243 thousand shares sold short, which is 1.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730135723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 8.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Chemed's Recent Short Interest

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 15 years by 6.88% on an annualized basis producing an average annual return of 18.99%. Currently, Chemed has a market capitalization of $9.04 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 15 years ago, it would be worth $13,304.94 today based on a price of $602.98 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729890009_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $13,000 Today

A large exercise of company stock options by Nicholas M. Westfall, Executive Vice President at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) was disclosed in a new SEC filing on October 23, as part of an insider exercise.
What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000095017024116574//Archives/edgar/data/19584/000095017024116574/0000950170-24-116574-index.htm">U.S. Securities and Exchange Commission</a>, Westfall, Executive Vice President at Chemed, exercised stock options for 0 shares of CHE. The transaction value amounted to $0.
As of Thursday morning, Chemed shares are up by 0.27%, with a current price of $594.75. This implies that Westfall's 0 shares have a value of $0.
<h3>Delving into Chemed's Background</h3>
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
<h3>Chemed's Financial Performance</h3>
Revenue Growth: Chemed displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 7.6%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 34.59%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Chemed's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 4.7.
</li>
</ul>
Debt Management: Chemed's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Chemed's P/E ratio of 30.06 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.88, Chemed's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 19.54, Chemed presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Breaking Update: Nicholas M. Westfall Engages In Options Exercise At Chemed

In a new SEC filing on October 23, it was revealed that Witzeman, VP &amp; Chief Financial Officer at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), executed a significant exercise of company stock options.
What Happened: Witzeman, VP &amp; Chief Financial Officer at Chemed, exercised stock options for 0 shares of CHE stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000095017024116588//Archives/edgar/data/19584/000095017024116588/0000950170-24-116588-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The exercise price of the options was $0.0 per share.
Chemed shares are trading up 0.27% at $594.75 at the time of this writing on Thursday morning. Since the current price is $594.75, this makes Witzeman's 0 shares worth $0.
<h3>Get to Know Chemed Better</h3>
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
<h3>Financial Milestones: Chemed's Journey</h3>
Revenue Growth: Chemed's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 7.6%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 34.59%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 4.7, Chemed showcases strong earnings per share.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.12.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 30.06 is lower than the industry average, implying a discounted valuation for Chemed's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.88 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 19.54, Chemed's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Michael D Witzeman Decides To Exercise Options At Chemed

Brian C Judkins, VP and Chief Legal Officer at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), reported a large exercise of company stock options on October 23, according to a new SEC filing.
What Happened: Judkins, VP and Chief Legal Officer at Chemed, made a strategic move by exercising stock options for 0 shares of CHE as detailed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000095017024116602//Archives/edgar/data/19584/000095017024116602/0000950170-24-116602-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $0.
The latest update on Thursday morning shows Chemed shares down by 0.0%, trading at $593.15. At this price, Judkins's 0 shares are worth $0.
<h3>All You Need to Know About Chemed</h3>
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
<h3>Chemed: Financial Performance Dissected</h3>
Revenue Growth: Chemed displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 7.6%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 34.59%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Chemed's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 4.7.
</li>
</ul>
Debt Management: Chemed's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 30.06 is lower than the industry average, implying a discounted valuation for Chemed's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.88 is above industry norms, reflecting an elevated valuation for Chemed's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 19.54, Chemed could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Brian C Judkins At Chemed Exercises Options

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 7.74% on an annualized basis producing an average annual return of 16.29%. Currently, Chemed has a market capitalization of $9.15 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 20 years ago, it would be worth $20,748.94 today based on a price of $610.18 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729521030_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chemed Stock In The Last 20 Years

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/10/01/final-trades-exxon-chemed-las-vegas-sands-and-the-ieo.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management picked iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEO#NYSE">IEO</a>) saying oil stocks are his hedge against <a href="https://www.benzinga.com/news/global/24/10/41126038/iran-attacks-israel-with-missiles-middle-east-tensions-escalates-s-p-500-stocks-bitcoin-fall-as-oil">escalating conflict with Iran</a>.
Jim Lebenthal of Cerity Partners said Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) is having a great year and is 3% away from its all-time high.
Exxon Mobil&#8217;s asset sale deal with Seplat Energy in Nigeria could be approved soon. On Tuesday, Nigeria's President, Bola Ahmed Tinubu, said, "As such, the ExxonMobil Seplat divestment will receive ministerial approval in a matter of days, having been concluded by the regulator, NUPRC, in line with the <a href="https://www.benzinga.com/markets/equities/24/10/41120426/exxonmobils-1-28b-nigerian-asset-sale-deal-nears-completion">Petroleum Industry Act, PIA."</a> 
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kari Firestone of Aureus Asset Management named Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) as her final trade.
Chemed will release financial results for the third quarter ended Sept. 30 on Tuesday, Oct. 29, after the closing bell on the New York Stock Exchange.
Stephanie Link of Hightower picked Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), a China play.
On Oct. 1, Wells Fargo analyst Daniel Politzer maintained Las Vegas Sands with an Overweight rating and raised the price target from $53 to $60.
Price Action:
<ul>
<li>iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF gained 2.2% during Tuesday's session.</li>
<li>Exxon Mobil shares gained 2.3% to settle at $119.93 on Tuesday.</li>
<li>Chemed shares fell 1.4% to close at $592.79 during Tuesday's session.</li>
<li>Las Vegas Sands shares gained 3% to close at $51.83 on Tuesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">Jim Cramer Hand Picks These 3 Stocks To Ride The Crest Of The Chinese Stimulus Frenzy</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

Exxon Mobil, Chemed, Las Vegas Sands And More On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Exxon Mobil, Chemed, Las Vegas Sands, iShares U.S. Oil & Gas Exploration & Production ETF

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amed#NASDAQ">AMED</a>) and Chemed (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/che#NYSE">CHE</a>). But which of these two stocks presents investors with the better value opportunity right now? Let&#39;s take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Amedisys and Chemed are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that AMED has an improving earnings outlook. But this is only part of the picture for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
AMED currently has a forward P/E ratio of 20.73, while CHE has a forward P/E of 25.41. We also note that AMED has a PEG ratio of 1.89. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. CHE currently has a PEG ratio of 2.26.
Another notable valuation metric for AMED is its P/B ratio of 2.68. Investors use the P/B ratio to look at a stock&#39;s market value versus its book value, which is defined as total assets minus total liabilities. By comparison, CHE has a P/B of 7.47.
These metrics, and several others, help AMED earn a Value grade of B, while CHE has been given a Value grade of C.
AMED stands above CHE thanks to its solid earnings outlook, and based on these valuation figures, we also feel that AMED is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2343525/amed-or-che-which-is-the-better-value-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2343525">To read this article on Zacks.com click here.</a>

Health Care

General

AMED

AMED Or CHE: Which Is The Better Value Stock Right Now?

In a new SEC filing on September 6, it was revealed that Westfall, Executive Vice President at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), executed a significant exercise of company stock options.
What Happened: Westfall, Executive Vice President at Chemed, made a strategic move by exercising stock options for 15,333 shares of CHE as detailed in a Form 4 filing on Friday with the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000095017024104251//Archives/edgar/data/19584/000095017024104251/0000950170-24-104251-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $1,564,885.
The latest update on Friday morning shows Chemed shares down by 0.0%, trading at $573.8. At this price, Westfall's 15,333 shares are worth $1,564,885.
<h3>About Chemed</h3>
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
<h3>Financial Insights: Chemed</h3>
Revenue Growth: Chemed's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 7.6%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 34.59%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 4.7, Chemed showcases strong earnings per share.
</li>
</ul>
Debt Management: Chemed's debt-to-equity ratio is below the industry average. With a ratio of 0.12, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 29.08, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.75 is above industry norms, reflecting an elevated valuation for Chemed's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 18.9, Chemed's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Major Exercise Alert: Nicholas M. Westfall Exercises Options Worth $1.56M At Chemed

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has fallen 14.22% since its last report. The company recently reported that it has 249 thousand shares sold short, which is 1.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724874323_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 9.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Chemed's Recent Short Interest

Disclosed on August 1, Nicholas M. Westfall, Executive Vice President at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000095017024089186//Archives/edgar/data/19584/000095017024089186/0000950170-24-089186-index.htm">U.S. Securities and Exchange Commission</a> on Thursday outlined that Westfall executed a sale of 2,000 shares of Chemed with a total value of $1,123,160.
Tracking the Friday's morning session, Chemed shares are trading at $588.44, showing a down of 0.0%.
<h3>About Chemed</h3>
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
<h3>Financial Milestones: Chemed's Journey</h3>
Revenue Growth: Over the 3 months period, Chemed showcased positive performance, achieving a revenue growth rate of 7.6% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 34.59%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Chemed's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 4.7.
</li>
</ul>
Debt Management: Chemed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: Chemed's P/E ratio of 29.82 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.85 is above industry norms, reflecting an elevated valuation for Chemed's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 19.38 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chemed Executive Vice President Trades Company's Stock

On August 1, it was revealed in an SEC filing that Michael D Witzeman, VP &amp; Chief Financial Officer at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000095017024089202//Archives/edgar/data/19584/000095017024089202/0000950170-24-089202-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Witzeman, VP &amp; Chief Financial Officer at Chemed, a company in the Health Care sector, just exercised stock options worth 7,948 shares of CHE stock with an exercise price of $471.74.
During Friday's morning session, Chemed shares down by 0.0%, currently priced at $588.44. Considering the current price, Witzeman's 7,948 shares have a total value of $927,531.
<h3>Unveiling the Story Behind Chemed</h3>
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
<h3>Financial Insights: Chemed</h3>
Revenue Growth: Chemed's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 7.6%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: With a high gross margin of 34.59%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Chemed's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 4.7.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.12, Chemed adopts a prudent financial strategy, indicating a balanced approach to debt management.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 29.82, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.85, Chemed's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Chemed's EV/EBITDA ratio at 19.38 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Activity Update: Michael D Witzeman Executes Options Exercise, Resulting In $927K At Chemed

Nicholas M. Westfall, Executive Vice President at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), reported an insider sell on July 31, according to a new SEC filing. 
What Happened: Westfall's recent move involves selling 2,000 shares of Chemed. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000095017024088299//Archives/edgar/data/19584/000095017024088299/0000950170-24-088299-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value is $1,123,160.
Tracking the Thursday's morning session, Chemed shares are trading at $579.99, showing a up of 1.72%.
<h3>Delving into Chemed's Background</h3>
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
<h3>Key Indicators: Chemed's Financial Health</h3>
Revenue Growth: Chemed displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 7.6%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 34.59%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Chemed's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 4.7.
</li>
</ul>
Debt Management: Chemed's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 28.9, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.73 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 18.78 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: Nicholas M. Westfall Offloads $1.12M Worth Of Chemed Stock

Revealing a significant insider sell on July 31, Nicholas M. Westfall, Executive Vice President at Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>), as per the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000019584/000095017024088299//Archives/edgar/data/19584/000095017024088299/0000950170-24-088299-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Westfall sold 2,000 shares of Chemed. The total transaction value is $1,123,160.
During Wednesday's morning session, Chemed shares down by 0.13%, currently priced at $565.42.
<h3>Delving into Chemed's Background</h3>
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
<h3>Chemed: Delving into Financials</h3>
Revenue Growth: Chemed's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 7.6%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 34.59%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Chemed's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 4.7.
</li>
</ul>
Debt Management: Chemed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 28.69 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.7 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 18.64 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000019584">Check Out The Full List Of Chemed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chemed Recent Insider Activity

Upward Revision to Guidance for 2024
VITAS 2024 revenue, prior to Medicare Cap, is estimated to increase 16.3% to 17.3% when compared to 2023. ADC is estimated to increase 13.3% to 14.4%. Full year adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 19.3% to 19.7%. We are currently estimating $8.5 million in Medicare Cap billing limitations in calendar 2024. The cost of the retention program negatively impacted VITAS' 2023 full year adjusted EBITDA by 159 basis points.
Covenant Health is estimated to contribute approximately $30 million to $32 million of revenue to VITAS' full year revenue. There is no estimated Medicare Cap billing limitation expected related to Covenant Health. This translates into adjusted net income attributable to Covenant Health of $5.5 million to $6.0 million and adjusted EBITDA of $8.0 million to $8.5 million.
Roto-Rooter is forecasted to have a 4.0% to 5.0% revenue decline in 2024 compared to 2023. Roto-Rooter's adjusted EBITDA margin for 2024 is expected to be 26.5% to 27.0%.
Based on the above, full-year 2024 earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $23.55 to $23.80. This guidance assumes an effective corporate tax rate on adjusted earnings of 24.3% and a diluted share count of 15.25 million shares. Chemed's previously issued 2024 guidance range was $23.30 to $23.70. Chemed's 2023 reported adjusted earnings per diluted share was $20.30.

Chemed Raises FY24 EPS From $23.30-$23.70 To $23.55-$23.80 Vs $23.21 Est.

TimesSquare U.S. Focus Growth Strategy Q3 2024 Commentary

Chemed Q3 2024 Earnings Preview

Here are the major earnings after the close today

Chemed Non-GAAP EPS of $5.64 misses by $0.12, revenue of $606.2M misses by $6.02M

Reports Q2 revenue $606.2M vs. $564.5M last year. VITAS segment operating results: Net Patient Revenue of $391.4 million, an increase of 17.3%, Ave...

Chemed reports Q2 EPS $5.64 vs. $4.93 last year

In a report released today, Joanna Gajuk from Bank of America Securities reiterated a Buy rating on Chemed (CHE – Research Report), with a price ta...

Chemed's Robust Vitas Growth and Strategic Opportunities Justify Buy Rating Despite Roto Challenges

Chemed Corporation (CHE) Q3 2024 Earnings Call Transcript

Chemed ( ($CHE) ) has realeased its Q3 earnings. Here is a breakdown of the information Chemed presented to its investors. Chemed Corporation, oper...

Chemed Corporation Reports Mixed Q3 2024 Results

RBC Capital analyst Ben Hendrix maintained a Buy rating on Chemed (CHE – Research Report) today and set a price target of $633.00. The company's sh...

RBC Capital Remains a Buy on Chemed (CHE)

RBC Capital lowered the firm's price target on Chemed (CHE) to $633 from $697 and keeps an Outperform rating on the shares after its Q3 earnings. T...

Chemed price target lowered to $633 from $697 at RBC Capital

ALSN

APAM

ATGE

ATOM

BGFV

BMRN

BRSP

CAKE

CHCT

CRWD

CTAS

CTRE

ENVX

EXEL

EXLS

FSLR

GOOG

HRZN

ILPT

JBGS

LBTYA

LBTYK

LFUS

LFVN

LSTR

LYSCF

MDLZ

MFIN

ORLY

PILBF

PRTS

QRVO

RDDT

RMBS

SAGE

SNAP

STAG

TRTX

VEEV

VRNS

VRSK

WERN

Press Releases

Chemed Reports First-Quarter 2024 Results

Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2024

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

Chemed Corporation to Present at the Jefferies 2024 Global Healthcare Conference

Chemed To Report Second-Quarter 2024 Earnings July 24, Related Conference Call To Be Held On July 25

Chemed Reports Second-Quarter 2024 Results

Chemed Corporation Declares Quarterly Dividend of 50 Cents

Chemed To Report Third-Quarter 2024 Earnings October 29, Related Conference Call To Be Held On October 30

Chemed Reports Third-Quarter 2024 Results

Chemed Corporation to Present at the UBS 2024 Global Healthcare Conference

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Chemed

Vendite allo scoperto

Chemed (NYSE:CHE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO